Bitopertin

Drug Profile

Bitopertin

Alternative Names: R-1678; RG 6718; RG-6178; RG1678; RO-4917838

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class Antipsychotics; Piperazines; Pyridines; Small molecules
  • Mechanism of Action Glycine transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obsessive-compulsive disorders; Schizophrenia

Most Recent Events

  • 01 Dec 2014 Roche completes a phase III trial in Schizophrenia in USA, Bulgaria, China, Czech Republic, Italy, Russia and Japan (NCT01235559; EudraCT2010-020718-26; WN25305)
  • 16 Oct 2014 Discontinued - Phase-III for Schizophrenia in USA, Turkey, Netherlands, Chile, Ukraine, Taiwan, Spain, Poland, Lithuania, Slovakia, Latvia, Germany, Canada, Brazil, Finland, India, Hungary, France, Columbia, Argentina, South Korea, Mexico, Romania, Russia, United Kingdom, Italy, Sweden, Czech Republic, Australia, China, Bulgaria, Japan (PO) (Roche pipeline)
  • 01 Oct 2014 Roche withdraws a phase I pharmacokinetics trial prior to initiation for Healthy volunteers in France (NCT02019290)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top